pSivida Corp. Reports Third Quarter 2014 Results
Business Wire - 1 hr 49 mins ago
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its third quarter ended March 31, 2014.
pSivida Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur at ARVO Annual Meeting
Business Wire - Mon May 05, 2:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur(TM) technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).
pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Fri May 02, 7:01AM CDT
pSivida Corp. (NASDAQ
pSivida to commercialise ILUVIEN for DME in Australia/New Zealand through STA
M2 - Tue Apr 29, 5:13AM CDT
Drug delivery company pSivida (NasdaqGM
pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN(R) for DME
Business Wire - Mon Apr 28, 6:06AM CDT
pSivida Corp. (NASDAQ
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
Business Wire - Wed Apr 23, 7:45AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA. pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss sustained delivery of antibodies and other large biologics with pSivida's Tethadur(TM) technology.
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGM
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences
Business Wire - Tue Apr 01, 9:09AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss pSivida's Tethadur(TM) technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
pSivida Corp. Announces $7.0 Million Investment by RA Capital
Business Wire - Thu Mar 13, 8:46AM CDT
pSivida Corp. (NASDAQ
10-Q: PSIVIDA CORP.
Edgar Online - Wed Feb 12, 9:31AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
pSivida Announces ILUVIEN(R) for DME Accepted by National Health Service Scotland
Business Wire - Mon Feb 10, 8:05AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN(R) for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes (those that have undergone cataract surgery).
pSivida Corp. Reports Second Quarter 2014 Results
Business Wire - Fri Feb 07, 3:00PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11
Business Wire - Thu Feb 06, 9:24AM CST
pSivida Corp. (NASDAQ
Research and Markets: Commercial Construction in New Zealand to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfx4k6/commercial) has announced the addition of the "Commercial Construction in New Zealand to 2017: Market Forecast" report to their offering.
pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Thu Jan 30, 3:39PM CST
pSivida Corp. (NASDAQ
3 Stocks Under $10 Moving Higher
at The Street - Wed Jan 29, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.